Microseminoprotein, prostate associated (MSMP)

Microseminoprotein, prostate associated (MSMP), is a secreted member of the beta-microseminoprotein family and acts as a chemotactic cytokine by binding to C-C chemokine receptor type 2 (CCR2), with a strong affinity for the CCR2B isoform. MSMP drives chemotaxis of monocytes and lymphocytes and plays a central role in modulating inflammatory responses, tissue remodeling, and tumorigenesis, especially in prostate and ovarian cancers. Its expression increases during liver fibrosis, cirrhosis, acute kidney injury, and other inflammatory conditions, where it facilitates recruitment of immune cells and pathological tissue responses. MSMP has also emerged as a mediator of resistance to antiangiogenic (anti-VEGF) therapies via MAPK signaling and is under investigation as a therapeutic target for conditions involving CCR2-dependent inflammation and tissue injury. There are no approved drugs directly targeting MSMP, but neutralizing antibodies have shown efficacy in experimental models.

Other names

Prostate-associated microseminoproteinPSMPPC-3-secreted microproteinPC3 prostate cancer cell-secreted microprotein

PSMP/MSMP acts as a high-affinity ligand for CCR2, mediating chemotactic migration of immune cells. Contributes to inflammatory signaling and tissue remodeling via CCR2. Enhancement of endothelial tube formation and angiogenic resistance through MAPK signaling in hypoxic tumor microenvironments. Neutralizing MSMP reduces kidney injury in preclinical models.